This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Drug: Scheduling of the time of pembrolizumab infusions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 58
- Registration Number
- NCT06882174
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
Phase 2
Not yet recruiting
- Conditions
- PneumonitisImmune-related Adverse Event
- Interventions
- Other: Arm 1- Usual careDrug: Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 94
- Registration Number
- NCT06860542
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 1
- Registration Number
- NCT06827886
- Locations
- 🇨🇦
Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Canada
COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma
- Interventions
- Drug: Levothyroxine Oral Tablet [Synthroid]
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 70
- Registration Number
- NCT06790589
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient with Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 1
- Registration Number
- NCT06789081
PET/MRI in Rectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Total Neo-adjuvant TherapyOther: 18FDG-PET/MRI scan
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT06057831
Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 27
- Registration Number
- NCT06001125
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Canada
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
Phase 2
Recruiting
- Conditions
- Colorectal CancerLiver Metastasis Colon Cancer
- Interventions
- Radiation: stereotactic body radiation treatment (SBRT)
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 24
- Registration Number
- NCT05775146
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
Phase 2
Recruiting
- Conditions
- Prostate CancerOncology
- Interventions
- Drug: [18]F-PSMA-1007
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 248
- Registration Number
- NCT05712174
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
PSMA-PET/CT Registry
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Diagnostic Test: [18F]-PSMA-1007
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 128
- Registration Number
- NCT05709535
- Locations
- 🇨🇦
Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath